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CONTEXT AND OBJECTIVE: Cancer patients undergoing bone marrow transplantation (BMT) often re-
quire nutritional therapy due to treatment toxicities. The aim here was to evaluate the use of tube feeding 
and its applicability, indications, contraindications and complications in these patients. 
DESIGN AND SETTING: Prospective observational study conducted at a public university in São Paulo 
between January 2002 and August 2007. 
METHODS: The patients were followed up daily in the BMT unit by a research dietitian. Tube feeding was 
indicated when oral supplementation proved to be insufficient, when the patient had severe malnutrition 
or there was an impediment to use of oral feeding. It was contraindicated in the presence of gastroin-
testinal toxicity of grade 3 and 4 or other conditions that implied a risk or hindered its use or placement. 
Complications of tube feeding were divided into minor and major, according to whether they had life-
threatening implications. 
RESULTS: Forty-two (47.2%) patients had indications for tube feeding: the main reasons were transplanta-
tion inadequate food and supplement intake, insufficient intake with malnutrition or weight loss, severe 
malnutrition or need for oral fasting. Thirty-one (73.8%) received tube feeding: 11 autologous and 20 al-
logenic patients (P = 0.04). The main contraindications were severe gastrointestinal toxicities and sinusitis. 
Minor complications from tube feeding were more prevalent in patients with allogenic BMT, but no major 
complications were observed. 
CONCLUSION: Enteral nutrition is a feasible procedure in patients undergoing BMT and should be en-
couraged. The main difficulty in BMT patients, in relation to tube feeding, is gastrointestinal toxicities. 
reSUMO
CONTEXTO E OBJETIVO: Pacientes com câncer submetidos ao transplante de medula óssea (TMO) fre-
quentemente necessitam de terapia nutricional devido às toxicidades do tratamento. O objetivo foi avaliar 
uso de sonda enteral, aplicabilidade, indicações, contraindicações e complicações nesses pacientes.
TIPO DE ESTUDO E LOCAL: Estudo observacional prospectivo, conduzido de janeiro de 2002 a agosto de 
2007 em uma universidade pública em São Paulo.
MÉTODOS: Os pacientes foram acompanhados diariamente na unidade de TMO por uma nutricionista 
da pesquisa. Indicações de sonda: suplementação oral insuficiente, desnutrição grave, ou alguma con-
traindicação para alimentação via oral. A contraindicação da sonda ocorreu na presença de toxicidades 
gastrintestinais de grau 3 e 4 ou outras condições que implicassem em risco ou impedissem seu uso ou 
passagem. As complicações da sonda foram divididas em menores e maiores, de acordo com implicações 
para o risco de vida.
RESULTADOS: Quarenta e dois (47,2%) pacientes tiveram indicações de nutrição por sonda: os principais 
motivos foram: ingestão alimentar e de suplemento inadequada, ingestão insuficiente com desnutrição 
ou perda de peso, desnutrição grave ou necessidade de jejum. Trinta e um (73,8%) pacientes usaram 
sonda: 11 com transplantes autólogos e 20 alogênicos (P = 0,04). As principais contraindicações foram 
toxicidades gastrintestinais graves e sinusite. Complicações leves com a sonda foram mais prevalentes nos 
pacientes em TMO alogênico, mas nenhuma complicação grave foi observada.
CONCLUSÃO: O uso de sonda enteral é um procedimento factível em pacientes durante o TMO e deve ser 
encorajado. A principal dificuldade nesse grupo em relação ao uso de sonda foi a toxicidade gastrintestinal.
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INTRODUCTION
Bone marrow transplantation (BMT) or hematopoietic stem cell 
transplantation (HSCT) is a recognized therapeutic method for 
a variety of hematologic malignancies, congenital abnormalities 
and malignancies. The procedure is used to restore bone marrow 
function in patients receiving intensive chemotherapy and radia-
tion, through infusion of progenitor cells or stem cells with an 
ability to multiply and differentiate into all types of mature blood 
cells: red cells, white cells and platelets.1
The transplants may be autologous or allogenic, depend-
ing on the origin of the cells. When the cells originate from the 
patient, the transplant is autologous, but when they are donated 
by another individual, it is allogenic. If the donor is an identical 
twin, the transplant is called syngenic.1,2
The complications from BMT can be acute or chronic and 
depend on the underlying disease and its initial condition before 
the procedure, the type of transplant, the chemotherapy and the 
preparatory regimen for radiotherapy. The main post-trans-
plant complications include bleeding, infections, organ failure, 
graft versus host disease (GVHD), graft failure or rejection, and 
recurrent disease.2
Besides these complications, nutritional status is strongly 
affected by the process of BMT. The reduced protein intake, 
for example, may influence immune function during metabolic 
stress. Thus, studies have demonstrated the importance of adjust-
ing the energy needs to maintain a zero nitrogen balance.3-5
Patients who receive BMT often require nutritional support 
because of their reduced food intake, which is associated with the 
toxicities of the conditioning regimen, especially in the gastroin-
testinal tract.5,6
Patients receiving allogenic BMT undergo a conditioning 
regimen with high-dose chemotherapy combined with total body 
irradiation, thereby leading to immunosuppression. The body 
irradiation is extremely toxic and leads to severe and prolonged 
mucositis. These patients’ immunity is more highly compro-
mised and they are at greater risk of overall complications than 
are those who undergo autologous BMT. Therefore, it is believed 
that patients who undergo allogenic BMT are also at greater risk 
of nutritional and metabolic complications and therefore need 
specialized nutritional support.7 Total parenteral nutrition (TPN) 
has been the method most commonly used to provide nutrients 
during BMT. However, circumstances such as risk of infection 
and lipid and glucose metabolism disorders may limit its use in 
these patients.8
OBJECTIVE
Since it is known that patients undergoing BMT often require 
nutritional support due to treatment toxicities, the objective of the 
present study was to evaluate the use of enteral nutrition through 
tube feeding and its applicability, indications, contraindications 
and complications in patients undergoing BMT, with compari-
sons between autologous and allogenic transplants.
METHODS
This was a prospective observational study carried out from Jan-
uary 2002 to August 2007, among patients admitted to undergo 
autologous or allogenic BMT procedures. The study was con-
ducted in accordance with a follow-up protocol from the BMT 
research unit at a pediatric oncology institute in a public univer-
sity in São Paulo. 
The study included all patients diagnosed with cancer for 
whom BMT was indicated, and the study excluded those whose 
family or legal guardian (and the patient, if over 18 years) had not 
agreed to sign the consent form, thereby refusing to participate. 
Patients who had been referred for transplantation but were not 
suffering from cancer were also excluded.
The patients were followed up daily by a research dieti-
tian, using a standardized report form schedule that had been 
developed to gather data on food intake; gastrointestinal signs 
and symptoms; oral supplements; administration of and indi-
cations and contraindications for enteral and parenteral nutri-
tional support; the antineoplastic treatment protocol; and other 
treatments. To estimate the total daily energy requirement, we 
used the World Health Organization (WHO) or Harris Benedict 
equation, according to the age group.9-11 A calculation of baseline 
energy expenditure (EE) plus a factor of 1.2 (illness) was applied 
in order to obtain the total EE (TEE).
 Weight-for-height (W/H) Z-scores from < -1.0 to -2.0 among 
children12 and body mass index (BMI) from greater than or equal 
to the fifth percentile to greater than the fifteenth percentile 
among adolescents13 were considered to represent mild malnu-
trition; and W/H Z-scores < -2.0 in children and less than the 
fifth percentile of BMI in adolescents were considered severe.14 
In young adults, the WHO cutoff values15 were applied: < 18.5 for 
mild and < 17 for severe malnutrition. 
Nutritional management
Indications for nutritional support were made in accordance 
with the routine protocol of the transplantation unit. They 
were applied by the nutrition team and consisted of indica-
tions of nutritional supplementation when the food intake was 
insufficient (less than 70-80% of energy needs) for three to 
five days.
Enteral tube feeding was indicated when: oral food and 
supplementation proved to be inadequate (less than 50% of 
energy needs); the patient had insufficient food and supple-
ment intake, with malnutrition or weight loss; the patient had 
severe malnutrition or he or she had an impediment to use 
of oral feeding. After the nutrition team had made an indica-
tion for tube use, the patient underwent a clinical evaluation 
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by the oncologist and the nursing staff, in order to implement 
this procedure.
Placement or use of the tube was contraindicated by the 
medical staff if the patient presented gastrointestinal toxicity of 
grade 3 or 4, or other medical complications that resulted in risk 
or could impede its use or placement. Parenteral nutrition was 
therefore administered when previous procedures had not been 
successful or were contraindicated.
The complications of tube feeding were divided into minor 
and major, according to whether they had life-threatening impli-
cations. Minor complications, referred to as non-life-threatening, 
comprised categories such as problems with the tube (inadvertent 
tube dislodgement or tube clogging), intensification of episodes of 
vomiting or diarrhea, colic or abdominal pain and infection in the 
oral cavity. Major complications were those that were systemic and 
life-threatening, and included malpositioned feeding tubes involv-
ing inadvertent placement into the respiratory tract, bleeding or 
injury in the oral cavity or gastrointestinal tract, perforation of the 
esophagus or stomach, disrupted breathing (obstruction of nasal 
breathing), sinusitis, epistaxis or aspiration pneumonia.16
Statistical analysis
The data were registered and analyzed using the NCSS/PASS sta-
tistical software.17 Differences between groups were investigated 
using the Mann-Whitney test for continuous variables. For cat-
egorical variables, the chi-square test was applied. 
The sample size was calculated considering an estimated rate 
of 30% for the malnutrition outcome in the autologous group and 
60% in the allogenic group, a significance level of 5% (chance of 
type 1 error or alpha = 0.05) and a power of 80% (chance of type 
2 error or beta = 0.2).
Ethics committee
The nutritional support protocol from which this analysis was 
derived was approved by the Institutional Review Board/Eth-
ics Committee of Universidade Federal de São Paulo — Escola 
Paulista de Medicina (Unifesp-EPM), under protocol num-
ber 0132/06. Informed consent was obtained from the parents, 
guardians or patients, after the study protocol had been explained 
to them.
RESULTS
Eighty-nine patients out of the 101 followed up during the study 
period fulfilled the inclusion criteria: 45 autologous transplant 
cases (50.6%) and 44 allogenic transplant cases (49.5%). Of these, 
forty-two (47.2%) had an indication for tube feeding: 18 autolo-
gous and 24 allogenic cases (Table 1). The patients’ demographic 
characteristics are shown in Table 2.
The mean of length of hospital stay was 30.4 days for autolo-







Acute myeloid leukemia 1 5.6
Hodgkin’s lymphoma 8 44.4
Non-Hodgkin’s lymphoma 4 22.2
Germ cell tumor 1 5.6
Neuroblastoma 3 16.7









Acute myeloid leukemia 5 20.8
Non-Hodgkin’s lymphoma 1 4.2
Biphenotypic leukemia 1 4.2
Ewing’s sarcoma 1 4.2
Total 42 100
Table 1. Cancer diagnoses according to the type of bone marrow 
transplant (BMT)
Transplant Male Female Children* Adolescents† Adults‡
Autologous  
(n = 11)
6 (55%) 5 (45%) 3 (27%) 6 (55%) 2 (18%)
Allogenic  
(n = 20)
13 (65%) 7 (35%) 12 (60%) 6 (30%) 2 (10%)
Total 19 12 15 12 4
Table 2. Demographic characteristics of the patients (n = 31)
*Children: 0-9 years; †Adolescents: 10-18 years; ‡Adults: over 18 years.
Among the patients who underwent autologous transplantation, 
the main reasons for the tube indication were inadequate oral 
food and supplement intake in eleven (61%), insufficient sup-
plement and food intake with malnutrition or weight loss in five 
(28%) and severe malnutrition in two (11%). Among the patients 
who underwent allogenic BMT, the reasons were: inadequate oral 
food and supplement intake in 17 (70.8%), insufficient oral food 
and supplement intake with malnutrition or weight loss in four 
(16.7%) and need for oral fasting in three (12.5%). Comparing 
the autologous and allogenic groups, there was no difference in 
the numbers of patients with inadequate food intake or with mal-
nutrition and weight loss. Table 3 shows the nutritional status of 
the group.
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In the light of these indications, 31 (73.8%) received tube 
feeding and 11 (26.2%) did not. Out of the 31 patients with the 
tube, 11 were autologous and 20 were allogenic cases (P = 0.04).
Among the autologous cases, the reasons associated with not 
using tube feeding were non-acceptance by the patient or fam-
ily in three cases, severe gastrointestinal toxicities in two, high 
risk of intestinal perforation in one and sinusitis in one. Among 
the allogenic cases, the reasons were the presence of significant 
sinusitis in two cases, gastrointestinal toxicity in one and high-
output colostomy in one.
Twelve patients (38.7%) received tube placement on day zero 
of BMT (day of infusion of bone marrow cells) and 19 (61.3%) 
after that day, ranging from one to 20 days later. The average 
duration of tube use was 14 days for allogenic cases and 20 days 
for autologous cases (P = 0.08).
A semi-elemental diet was required at some time during the 
treatment in 21/31 patients (67.7%): 81.8% of the autologous 
cases and 60% of the allogenic cases (difference not significant). 
The descriptions of the type of diet and tube position according 
to group are shown in Graph 1. No analysis was performed on 
the infusion of enteral diet.
Twenty patients only used the feeding tube as an addition to 
the oral route; the sum of these two routes contributed 79.6% of 
TEE. The average adequacy of energy intake only with tube feed-
ing was 51% for the whole group: 56% versus 38% for the autol-
ogous and allogenic cases, respectively (P = 0.08); 39.7% of the 
patients used a nasogastric tube feeding (NGT) and 46% used a 
nasoenteral tube (NET).
There were no major complications from tube feeding, but 
some minor complications were observed in 17 patients (54.8%): 
intensification of the episodes of vomiting or diarrhea with pro-
gression of the volume of diet in five (16.1%), tube dislodgement 
in six (19.4%), fungal infection in the oral cavity in three (9.7%) 
and problems with the tube (tube clogging) in two (6.5%).
Comparing the complications between the autologous and 
allogenic cases (36% versus 60%; not significant), intensification 
Graph 1. Description of feeding tube placement and type of diet 














NET = nasoenteral tube; NGT = nasogastric tube.
Bone marrow 
transplantation type
Nutritional status At admission Percentage At discharge Percentage
Autologous (n = 11)
Severe malnutrition 2 18 1 9
Mild malnutrition 2 18 3 27.3
Normal weight 7 63.6 6 54.5
Overweight/obese 0 0 0 0
Allogenic (n = 20)
Severe malnutrition 2 10 1 5
Mild malnutrition 0 0 0 0
Normal weight 12 60 12 60
Overweight/obese 6 30 4 20
Total (n = 31)
Severe malnutrition 4 12.9 2 6.5
Mild malnutrition 2 6.5 3 9.7
Normal weight 19 61.3 18 58
Overweight/obese 6 19.4 4 12.9
Table 3. Nutritional diagnosis of the patients before bone marrow transplant (at admission) and afterwards (at discharge) (n = 31)*
*Four patients were lost at discharge: one autologous case with normal weight at admission and three allogenic cases (one obese individual and two with 
normal weight at admission).
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of the episodes of vomiting or diarrhea was found in one (9.1%) 
versus four (20%), respectively. The three patients with fungal 
infection in the oral cavity belonged to the allogenic group. Tube 
clogging and tube dislodgement were found in 9% versus 5% and 
18.2% versus 20% in the autologous and allogenic cases, respec-
tively (not significant).
DISCUSSION
Currently, hematopoietic stem cell transplantation may be an 
alternative to conventional treatment that can be indicated for 
treating various malignant childhood tumors. According to a 
recent consensus, the main indications in pediatric oncology 
patients may be some leukemias and lymphomas and some solid 
tumors such as neuroblastoma, some central nervous system 
tumors, Wilms’ tumor, germ cell tumors and some bone tumors 
such as Ewing’s sarcoma.18
Patients undergoing this procedure are at greater nutritional 
risk because of the aggressiveness of the therapy. Gastrointestinal 
toxicities such as mucositis, nausea and vomiting are observed in 
all patients undergoing BMT.19
Parenteral nutrition is a method of nutritional therapy that 
is widely used and recommended as a choice for patients who 
undergo BMT, mainly because of the results of an earlier study 
that demonstrated that its prophylactic use had a positive impact 
on patient survival after three years of follow-up.20 However, the 
use of total parenteral nutrition (TPN) is also associated with an 
increased risk of complications, especially infectious and meta-
bolic diseases, for which the greatest risk may be among patients 
with severe immunosuppression, such as BMT patients. There-
fore, routine use of TPN is not warranted, unless toxicity or seri-
ous complications of the gastrointestinal tract, preclude the full 
use of enteral nutrition.21-24
Therefore, nutritional therapy has been widely recommended 
for pediatric patients undergoing BMT, and enteral nutrition 
through a feeding tube is preferred over TPN in the absence 
of severe mucositis.25 In the present study, severe gastrointes-
tinal toxicities and sinusitis were the main problems that con-
traindicated placement of tube feeding among the allogenic and 
autologous BMT patients. However, this group of patients who 
experienced such problems was receiving the only alternative to 
parenteral nutrition for support.
Several research groups have advocated the use of percutane-
ous endoscopic gastrostomy (PEG) for cancer patients, especially 
when nutritional therapy is required for a prolonged period.25-27 
Although this method has not been tested in BMT patients, it 
may be useful and feasible if used early, before lesions occur in the 
oral mucosa and gastrointestinal tract thereby preventing tube 
placement in situations of aplasia with severe thrombocytope-
nia. Even though all the procedures for tube placement were fol-
lowed, in accordance with the indications and contraindications, 
it was observed that more than 60% of the patients underwent 
tube placement after infusion of bone marrow cells, i.e. when the 
blood cell count was already very low and the lesions in the gas-
trointestinal mucosa were starting to emerge. Delay in indication 
of nutritional support may hamper the use of tube feeding, and 
predispose towards increased risk of complications. Therefore, 
early indication of tube feeding could benefit a greater number 
of patients, thereby reducing the need for TPN, or at least reduc-
ing its length of use.
On the other hand, some groups of experts are resistant 
to using tube feeding in BMT patients, believing that the pro-
cedure has a high risk due to gastrointestinal toxicities and the 
low platelet and leukocyte counts that occur in these individu-
als.4 Although usually considered to be a harmless procedure, 
blind placement of tube feeding may result in serious and even 
lethal complications. Given the widespread use of tube feeding in 
patients of all ages, even a small percentage of such problems may 
affect a significant number of people.16 In this study, tube feeding 
was used without major complications, thereby contributing 51% 
of TEE and demonstrating that the method was feasible in this 
population of cancer patients.
Enteral nutrition has been extensively recommended for 
adults and infants during cancer treatment.28-30 Several studies 
have found it to be feasible in patients with cancer undergoing 
BMT, with favorable evolution of nutritional status achieved by 
means of feeding tubes.31,33 Langdana et al. found that nutritional 
therapy through an aggressive program of enteral nutrition using 
feeding tubes was possible in a pediatric population that under-
went BMT, including patients who received conditioning with 
total body irradiation. They noted that this method contributed 
between 33% and 48% of energy requirements per kilogram of 
weight during the program.34
The main indications for use of tube feeding found in the 
present study were low food intake and malnutrition. Such con-
ditions are common in cancer patients who undergo BMT. There-
fore, nutritional support is crucial during this period in order to 
ensure a more favorable response to treatment, thereby improv-
ing the chances of cure and survival.
Patients receiving allogenic transplants underwent condi-
tioning regimens that were more aggressive, usually consist-
ing of a combination of extremely high doses of two or more 
chemotherapy regimens, often in combination with total body 
radiation. Such therapy is extremely toxic, with serious conse-
quences for the integrity of the gastrointestinal tract, and vari-
ous other toxic effects. Comparing the autologous and allogenic 
groups, no difference was found in relation to the causes of indi-
cation, i.e. the numbers of patients with inadequate food intake 
or with malnutrition or weight loss were not different. The aver-
age percentage of patients with adequate energy intake was 56% 
in autologous and 38% in allogenic cases, which demonstrated a 
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borderline difference. This difficulty may be associated with the 
type of transplant, thus showing that patients who underwent 
allogenic BMT were at higher nutritional risk.
In this study, no differences in the reasons that contraindi-
cate use or placement of tube feeding could be perceived between 
the types of BMT. However, with the exception of the refusal of 
patients or relatives to undergo this procedure, the main reasons 
that did not allow the use of tube feeding in both groups were 
severe gastrointestinal problems and the presence of sinusitis.
Patients undergoing BMT procedures are at increased risk of 
organ toxicity due to the aggressiveness of the therapeutic implants. 
Gastrointestinal toxicities such as mucositis, nausea and vomiting 
are expected in patients undergoing BMT.19 Several patients in this 
study had tube placement contraindicated for reasons relating to 
BMT complications, which frequently occur over the two weeks 
following infusion of marrow cells. This probably contributed 
towards the lower success of enteral nutrition. Even transfusion of 
platelets in the presence of severe thrombocytopenia or adminis-
tration of medications to control vomiting, in order to reduce the 
risk of tube feeding and improve the therapy, did not ensure full 
infusion volume of the diet planned to meet the requirements. This 
probably contributed towards the results in terms of energy supply, 
thereby reducing the efficacy of the therapy. 
Thus, this study highlights the importance of developing 
clinical trials using tube feeding and PEG at the beginning of 
the BMT treatment. This could provide nutritional support with 
less risk of infections and less use of TPN or its use for a shorter 
period. 
Moreover, early placement of percutaneous endoscopic gas-
trostomy (PEG) would eliminate the risks associated with the 
procedure for placing tubes in situations of marrow aplasia and 
severe toxicities of the gastrointestinal tract, as well as contraindi-
cations for placement of the tube, for the same reason. Therefore, 
this approach could ensure a more adequate supply of enteral diet 
throughout the period of transplantation, without loss of the tube 
accidentally or through vomiting, with increased diet tolerance, 
decreased risk and a positive impact on nutritional status and 
consequently on the prognosis.
Because of the frequency of gastrointestinal toxicities in these 
patients, especially mucositis and enteritis, changes in the formu-
lation of enteral feeding may be necessary in order to facilitate 
tolerance. In many cases, diets that are easier to digest and absorb 
are used. In this study, we observed that a semi-elemental diet 
was required at some time during the treatment in 81% of the 
autologous and 60% of the allogenic BMT patients. 
Bone marrow toxicity, which leads the patient to bone mar-
row failure, is one of the biggest challenges faced by the team, 
because of the high risk of death in this group. There is evidence 
that allogenic transplantation contributes more to the risk factors 
for overall complications, mainly due to increased inflammatory 
response, with higher synthesis of pro-inflammatory cytokines 
during this phase. This condition seems to be further aggravated 
in allogenic unrelated transplantation, which was not included in 
this study because, at that time, the institution had not yet per-
formed this type of BMT.8,35
Although no significant differences between autologous 
and allogenic cases were observed in this study, regarding the 
presence of minor complications from use of tube feeding, the 
patients who underwent allogenic BMT had a greater percentage 
of these complications, which were mainly gastrointestinal and 
infectious diseases, thus corroborating the data in the literature. 
The results also showed that patients who underwent allo-
genic BMT had more difficulty in achieving energy supply with 
nutritional support. This could be correlated with the greater 
number and severity of complications in this group, thereby also 
indicating higher nutritional risk and a worse clinical outcome. 
Finally, enteral nutrition through the tube was seen to be a 
feasible procedure in patients undergoing BMT. This procedure 
should be encouraged, in keeping with the recommendations for 
care in relation to gastrointestinal toxicities, mucosal lesions, risk 
of bleeding and other conditions that lead patients to the risk of 
acquiring infections. 
Moreover, early indication, correct choice of enteral feeding, 
specific care during tube placement procedures, attention to pro-
duction and administration of diet and appropriate use of medi-
cations can optimize the tube feeding method. Nevertheless, in 
the event of severe gastrointestinal toxicities, use of TPN should 
be considered when the patient requires nutritional support and 
tube feeding is temporarily contraindicated.
Hence, there is a need for controlled trials to assess the appli-
cability and benefits of nutritional support, in particular regard-
ing the use of tube feeding and PEG, and especially through 
investigating early indication.
CONCLUSION
Enteral nutrition is a feasible procedure in patients undergoing 
BMT and should be encouraged. The main difficulty faced by 
BMT patients in using tube feeding is gastrointestinal toxicities. 
It is important to conduct controlled clinical trials to assess the 
applicability and benefits of nutritional support, and in particu-
lar the applicability of tube feeding and PEG, with investigations 
on early indication.
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